Dunross & Co Holding Ltd.
Dunross & Co Holding Ltd. serves as the Dunross Group’s holding company and is headquartered in Paphos, Cyprus. The company employs six people and is located at 46 Ioanni Agroti, Paphos.
Dunross & Co S.A.
Dunross & Co S.A., located in central Luxembourg City, is a self-managed Special Investment Fund (SICAV-SIF). Supervised by the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg, the company focuses on equity investments in Breakout Nations. Shares are exclusively offered to its single shareholder, Dunross & Co Holding Ltd, directly or via wholly owned subsidiaries. Dunross & Co S.A. employs nine people.
Dunross & Co AB
Established in 1990, Dunross & Co AB is the founding entity of the Dunross Group. It currently acts as the holding company for several high-potential growth businesses, including:
- Cellectricon AB: A biotechnology company with innovative technologies for drug target development.
- Envirochem AB: A provider of environmentally friendly chemicals for heavy industries.
- Harmred Holding AB: A producer of tobacco-free snuff products.
Dunross & Co AB also provides group support services, such as administration. Based in Mölndal, the company employs two people.
Dunross Investment Ltd.
Dunross Investment Ltd., a subsidiary of Dunross & Co Holding Ltd., was established in 2007. The company specializes in direct and indirect investments in equities and bonds in Breakout Nations. It operates from Paphos, Cyprus, with one employee.
Ägir Invest AB
Ägir Invest AB, a subsidiary of Dunross & Co AB, focuses on private equity investments in Swedish companies. Dunross has historically played a key role in developing several businesses that have grown into successful enterprises. The most notable investments within Ägir Invest include:
- Cellectricon AB: A biotechnology company (96% ownership).
- Harmred Holding AB: A tobacco-free snuff company.
The company is based in Mölndal, Sweden.
Cellectricon AB
Cellectricon AB, owned 96% by Ägir Invest AB, is a biotechnology company specializing in patented, cutting-edge technology that enhances pharmaceutical companies’ ability to develop new drugs. Its primary focus is on diseases related to pain, the central nervous system, Alzheimer’s, Parkinson’s, and Huntington’s. The company is headquartered in Mölndal, and employs 18 people.